{
  "nctId": "NCT06867172",
  "briefTitle": "Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma",
  "officialTitle": "The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study",
  "protocolDocument": {
    "nctId": "NCT06867172",
    "filename": "Prot_SAP_ICF_000.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2025-02-20",
    "uploadDate": "2025-02-22T15:18",
    "size": 603493,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06867172/document/Prot_SAP_ICF_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 66,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2019-01-01",
    "completionDate": "2025-06-30",
    "primaryCompletionDate": "2025-03-31",
    "firstSubmitDate": "2024-09-27",
    "firstPostDate": "2025-03-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age 18 or older\n* Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size â‰¥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).\n\nExclusion Criteria:\n\n* No evidence of written informed consent\n* Patients with contraindications for endoscopy due to comorbidities\n* Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)\n* Acute pancreatitis at baseline imaging\n* Pancreatic surgery at baseline imaging in our department\n* Splenectomy\n* Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "increased prevalence of pancreatic steatosis in neoplastic cystic lesions",
        "description": "Increased prevalence of pancreatic steatosis in neoplastic cystic lesions (mostly premalignant lesions)",
        "timeFrame": "From enrollment up to 5 years"
      }
    ],
    "secondary": [
      {
        "measure": "Increased prevalence of pancreatic steatosis in PDAC",
        "description": "The investigators are looking for increased prevalence of pancreatic steatosis in patients with PDAC and its association with stage of PDAC and PDAC-related mortality",
        "timeFrame": "From enrollment up to 5 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:12.106Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}